NCT01884285 - AZD8186 First Time In Patient Ascending Dose Study | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

July 9, 2013

Primary Completion Date

March 31, 2019

Study Completion Date

February 7, 2020

Conditions

Advanced Castrate-resistant Prostate Cancer CRPCSquamous Non-Small Cell Lung Cancer sqNSCLCTriple Negative Breast Cancer TNBC

Interventions

DRUG

Part A: AZD8186 monotherapy

The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.

DRUG

Part B: AZD8186 monotherapy

Part B will be at a dose(s) and schedule(s) at or below from Part A

DRUG

Part C1: Abiraterone acetate combination with AZD8186

Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).

DRUG

Part D1: AZD2014 combination with AZD8186

Dose \& schedule finding of AZD8186 in combination with AZD2014

DRUG

Part D2 AZD2014 combination with AZD8186

Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1

DRUG

Part C2: Abiraterone acetate combination with AZD8186

Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)

Trial Locations (13)

8036

Research Site, Barcelona

10065

Research Site, New York

28223

Research Site, Pozuelo de Alarcón

48201

Research Site, Detroit

98109

Research Site, Seattle

02215

Research Site, Boston

53792-5666

Research Site, Madison

M5G 2M9

Research Site, Toronto

08035

Research Site, Barcelona

CB2 0QQ

Research Site, Cambridge

WC1E 6BT

Research Site, London

M20 4BX

Research Site, Manchester

SM1 2DL

Research Site, Sutton